Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
about
Potential contribution of gut microbiota and systemic inflammation on HIV vaccine effectiveness and vaccine design.Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.A novel polyepitope vaccine elicited HIV peptide specific CD4+ T cell responses in HLA-A2/DRB1 transgenic mice.The quest for an antibody-based HIV vaccine.A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques.Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination.HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.Virus-Like-Vaccines against HIV.Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates.Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.Intragastric administration of Lactobacillus plantarum and AT-2-inactivated SIV does not protect Indian rhesus macaques from intra-rectal SIV challenge nor reduce virus replication after transmission.Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials.The US Military Commitment to Vaccine Development: A Century of Successes and Challenges.Chronic schistosomiasis suppresses HIV-specific responses to DNA-MVA and MVA-gp140 Env vaccine regimens despite antihelminthic treatment and increases helminth-associated pathology in a mouse modelMucosal antibody responses to vaccines targeting SIV protease cleavage sites or full-length Gag and Env proteins in Mauritian cynomolgus macaques
P2860
Q40039516-D9CEC16B-6745-4A7B-8650-45E9AB250082Q40043685-1339FE9B-EE59-49A5-B00A-E3EF8B42067AQ40061333-E2B4E7B8-A2A4-47B5-88BA-94C443C600C2Q40354016-A011C3F8-083A-477A-88E9-6DEE4D0A31DAQ47296227-58A5FAB7-911E-44AA-9BF3-0279464D3B45Q47384731-0A776399-965A-4D01-9502-6ED27F2BE533Q47547483-B2E5B87C-4C98-4C49-AFA1-E9392EFBF71BQ47553316-386A68EB-737D-4802-BE9F-C76B2220F453Q50034030-382247CA-8665-4877-962E-EA48583D4E0CQ50043326-8A178269-6005-4DBF-AF3C-86E99CF2BD75Q50084407-F158E29B-3449-4E57-A620-849222FC7F89Q52680808-A48B6D6D-FF0F-4B9B-BE94-E7E937C2D821Q54230395-1C866F23-9D6B-4508-A049-3AB9AC582EC9Q55432397-DDCD3D1A-F169-4691-8338-EE316388AAD0Q56936216-D6B5CB4A-483E-4AD3-8D0C-92A13A272B23Q58699804-09C24D69-3DF8-44F8-A103-A99BD20EA5FC
P2860
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
@en
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
@nl
type
label
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
@en
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
@nl
altLabel
Complex immune correlates of protection in HIV-1 vaccine efficacy trials
@en
prefLabel
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
@en
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
@nl
P2860
P356
P1476
Complex immune correlates of protection in HIV-1 vaccine efficacy trials.
@en
P2093
Georgia D Tomaras
P2860
P304
P356
10.1111/IMR.12514
P577
2017-01-01T00:00:00Z